Adendra Launched To Unlock Immunotherapy Potential Of Dendritic Cells
Another Spin-Out From London’s Crick Institute
Executive Summary
Expertise in dendritic cells could help generate new targets in cancer and autoimmune disease immunotherapy.
You may also be interested in...
Cash Injection Puts Quell At Forefront Of Treg Therapy
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
Takeda Buys Out Partner GammaDelta In Cell Therapy Push
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.